Skip to content
Medical Health Aged Care

GILEAD WELCOMES FIRST REGIONAL CAR T-CELL TREATMENT CENTRE IN FAR NORTH QUEENSLAND

Gilead Sciences 3 mins read

Townsville University Hospital now qualified and able to provide CAR T therapy for people living with certain blood cancers  

 

Melbourne, Australia, 11 July 2024 – Kite, a Gilead company, today welcomed the opening of Australia’s first regional Chimeric Antigen Receptor (CAR) T-cell Treatment Centre at the Townsville University Hospital (TUH) in Far North Queensland. At an event to mark the opening of the TUH CAR T Treatment Centre, Gilead congratulated the Queensland Government for leading the way in narrowing the healthcare inequity gap by improving access to innovative cancer treatments for people impacted by blood cancers living in regional areas.

 

Queensland is currently the only state in Australia to have a CAR T Treatment Centre in both a metropolitan and regional area. With the TUH CAR T Treatment Centre now open, suitable patients in Far North Queensland can access CAR T treatment in Townsville, instead of having to travel to Brisbane or beyond to access treatment.

 

Ms Sharon Millman, CEO of Lymphoma Australia welcomed the TUH CAR T Treatment Centre, saying it would help lessen the significant burden on patients and families from rural and regional areas who would normally have to relocate temporarily to Brisbane to undergo treatment.

 

“CAR T therapy is now firmly established in the treatment pathway for lymphomas, so we are extremely pleased to see the first regional treatment site in Australia now open and able to offer CAR T therapy options to eligible lymphoma patients living in Far North Queensland,” Ms Millman said.

 

“This is a great first step towards more equitable access to CAR T for Australians living away from existing Treatment Centres. Where you live should not limit your ability to access cancer treatment, and we’d love to see other states and territories certified and able to offer CAR T treatment to eligible patients as soon as possible to reduce the significant burden caused by travel and temporary relocation,” Ms Millman added.

 

In Australia, CAR T Treatment Centres are currently located in Brisbane, Melbourne, Sydney and Perth. They include Royal Brisbane and Women’s Hospital, the Peter McCallum Cancer Centre and the Alfred Hospital in Melbourne, Royal Prince Alfred and Westmead Hospitals in Sydney and Fiona Stanley Hospital in Perth.

 

Gilead echoed Lymphoma Australia’s support for the new TUH CAR T Treatment Centre and their call for continued efforts to ensure greater equity in access to CAR T.

 

Jaime McCoy, General Manager, Gilead Sciences Australia and New Zealand commented “We believe Australians living with blood cancers who are eligible for CAR T should have an option to receive treatment as close to their home as possible, particularly as this highly specialised treatment requires remaining near the hospital for several weeks. This can place a significant burden on patients and their families.

 

“We remain committed to working with governments, patient advocacy groups and the clinical community to establish much needed additional CAR T treatment centres, particularly in SA, ACT, Tasmania and the NT where disappointingly there are no centres able to give treatment at all, meaning that patients must then relocate interstate for a period of time” she added.

 

- Ends -

Issued by SenateSHJ on behalf of Gilead Sciences.

Notes to editor: In relation to this media announcement, no compensation was provided to Ms Sharon Millman and the opinions expressed are her own.

About Kite 

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California, with commercial manufacturing operations in North America and Europe. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. 

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

 

Based in Melbourne, Gilead Sciences Australia and New Zealand employs over 100 people.

 

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, or follow Gilead on Twitter (@GileadSciences)

 

KITE PHARMA and the KITE LOGO are registered trademarks of Kite Pharma, Inc. GILEAD and the GILEAD Logo are registered trademarks of Gilead Sciences, Inc.or its related companies. Gilead Sciences Pty Ltd. Level 28, 385 Bourke St, Melbourne VIC 3000. AU-UNB-0843. Date of preparation July 2024.

 


Key Facts:

B-roll footage of CAR T mode of action and manufacturing available here: 

https://www.dropbox.com/scl/fo/9m4pgzxta3je82icqzljs/AN2hLgCSqJ0owIJ5y2t-9vw?rlkey=iraxrugg4y3ehcw7bjpngs7q3&dl=0

More from this category

  • Medical Health Aged Care
  • 24/07/2024
  • 18:40
Malaysia Healthcare Travel Council

Malaysia Healthcare Travel Council Launches Experience Malaysia Healthcare (EMH) Stories

KUALA LUMPUR, Malaysia, July 24, 2024 (GLOBE NEWSWIRE) -- Malaysia Healthcare Travel Council (MHTC) is proud to announce the premiere of EMH Stories, a limited-series video production showcasing the exceptional experience of the healthcare journey of healthcare professionals, patients and technology breakthrough within Malaysia's healthcare travel ecosystem.Experience Malaysia Healthcare (EMH) Stories is designed to provide an intimate and inspiring glimpse into the diverse and impactful stories within Malaysia's healthcare travel ecosystem. The series aims to demonstrate the expertise and specialization within Malaysia’s healthcare system, build the reputation and credibility of Malaysia's healthcare services, and increase awareness and visibility of the…

  • Medical Health Aged Care, Research Development
  • 24/07/2024
  • 15:46
National Rural Health Alliance

Changes to Patient Travel Subsidy Scheme will benefit rural patients

The removal of the Patient Travel Subsidy Scheme’s four-night rule by the Queensland government is applauded by the National Rural Health Alliance (the Alliance). Rural Queenslanders will no longer need to cover the first four nights of accommodation out of pocket from 1 August. This initiative will save Queenslanders who need to travel to access healthcare, hundreds of dollars, which add to the other costs of living and working outside of urban centres. “This is timely and necessary news for rural populations in Queensland,” said the Alliance Chief Executive Susi Tegen. “Many rural patients must travel over 50kms from their…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/07/2024
  • 15:17
Dementia Australia

Dementia Australia awards $385,000 to support dementia-friendly projects

Dementia Australia has awarded more than $385,000 in grants to support 27 communities across Australia to become more dementia-friendly. Each of the 27 community groups were awarded up to $15,000 to fund dementia-friendly initiatives tailored to the issues and opportunities in their area. Dementia Australia Executive Director Services, Advocacy & Research Dr Kaele Stokes said one of the keys to the success of such initiatives was that grant recipients would work closely with local people living with dementia. “We know that discrimination and social isolation have a big impact on people living with dementia,” Dr Stokes said. “With more than…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.